

Citi Pharma Limited

April 19, 2022

The General Manager Pakistan Stock Exchange Limited Stock Exchange Building Stock Exchange Road Karachi.

Financial results for the 3rd quarter ended March 31, 2022

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on April 19, 2022 at 02:30 PM at Lahore have approved the financial statements for the 3rd quarter ended on March 31, 2022 and recommended the following.

Cash Dividend	Nil	
Bonus Shares	Nil	
Right Shares	Nil	
Any other entitlement/corporate action	Nil	
Any other Price sensitive information	Nil	I

Financial results of the company for the 3rd quarter ended March 31, 2022 are enclosed.

Quarterly report of the Company for the 3rd quarter ended March 31, 2022 will be transmitted through PUCARS separately, within the specified time.

Yours Sincerely,

Muhammad Riaz **Company Secretary**











Citi Pharma Limited

CITI PHARMA LIMITED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED) FOR THE NINE MONTHS ENDED MARCH 31, 2022

		Three month ended		Nine Months Ended		
		March 31, 2022 (Un-audited)	March 31, 2021 (Un-audited)	March 31, 2022 (Un-audited)	March 31, 2021 (Audited)	
	Notes	Rupees				
Sales- Net		2,748,139,247	1,779,988,933	7,589,370,656	4,015,415,064	
Cost of sales		(2,394,782,158)	(1,604,806,678)	(6,534,612,959)	(3,410,122,993)	
Gross profit		353,357,089	175,182,255	1,054,757,697	605,292,071	
Administrative expenses		35,229,626	18,795,558	238,950,314	91,714,310	
Selling expenses		6,296,697	2,351,234	60,656,610	96,642,891	
Selling expenses		(41,526,323)	(21,146,792)	(299,606,924)	(188,357,201)	
Operating Profit		311,830,765	154,035,462	755,150,774	416,934,870	
Financial Charges		(18,206,305)	(18,714,184)	(52,333,402)	(22,061,842)	
		293,624,461	135,321,278	702,817,371	394,873,028	
Other income/(Loss)	10	45,264,633	2,731,558	134,519,491	2,091,243	
		338,889,094	138,052,837	837,336,862	396,964,271	
Other Expenses		(23,722,237)	(8,176,462)	(57,082,702)	(27,094,249)	
Profit before Taxation		315,166,857	129,876,375	780,254,160	369,870,023	
Taxation		(107,717,629)	(30,544,394)	(229,563,711)	(117,433,708)	
Profit for the period		207,449,228	99,331,981	550,690,450	252,436,315	
Earnings per share (EPS)						
- Basic and Diluted		0.92	0.74	2.43	3.30	











